Lisa M Jacola1, Doralina L Anghelescu2, Lacey Hall3, Kathryn Russell3, Hui Zhang4, Fang Wang4, Joanna B Peters3, Michael Rossi2, Jane E Schreiber5, Amar Gajjar6. 1. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN. Electronic address: lisa.jacola@stjude.org. 2. Department of Anesthesiology, St. Jude Children's Research Hospital, Memphis, TN. 3. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN. 4. Department of Biostatics, St. Jude Children's Research Hospital, Memphis, TN. 5. Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA. 6. Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN.
Abstract
OBJECTIVE: To examine the contribution of anesthesia exposure during treatment for childhood medulloblastoma to neurocognitive outcomes 3 years after tumor diagnosis. STUDY DESIGN: In this retrospective study, anesthesia data were abstracted from medical records for 111 patients treated with risk-adapted protocol therapy at St Jude Children's Research Hospital. Neurocognitive testing data were obtained for 90.9% of patients. RESULTS: For the 101 patients (62.4% male) who completed testing, mean age at diagnosis was 10.1 years, and 74.3% were staged to have average-risk disease. Anesthesia exposure during treatment ranged from 1 to 52 events (mean = 19.9); mean cumulative duration per patient was 21.1 hours (range 0.7-59.7). Compared with normative expectations (16%), the group had a significantly greater frequency of at-risk scores (<1 SD) on measures of intelligence (28.7%), attention (35.2%), working memory (26.6%), processing speed (46.7%), and reading (25.8%). Including anesthesia exposure duration to linear regression models accounting for age at diagnosis, treatment intensity, and baseline IQ significantly increased the predicted variance for intelligence (r2 = 0.59), attention (r2 = 0.29), working memory (r2 = 0.31), processing speed (r2 = 0.44), and reading (r2 = 0.25; all P values <.001). CONCLUSIONS: In survivors of childhood medulloblastoma, a neurodevelopmentally vulnerable population, greater exposure to anesthesia significantly and independently predicts deficits in neurocognitive and academic functioning. When feasible, anesthesia exposure during treatment should be reduced.
OBJECTIVE: To examine the contribution of anesthesia exposure during treatment for childhood medulloblastoma to neurocognitive outcomes 3 years after tumor diagnosis. STUDY DESIGN: In this retrospective study, anesthesia data were abstracted from medical records for 111 patients treated with risk-adapted protocol therapy at St Jude Children's Research Hospital. Neurocognitive testing data were obtained for 90.9% of patients. RESULTS: For the 101 patients (62.4% male) who completed testing, mean age at diagnosis was 10.1 years, and 74.3% were staged to have average-risk disease. Anesthesia exposure during treatment ranged from 1 to 52 events (mean = 19.9); mean cumulative duration per patient was 21.1 hours (range 0.7-59.7). Compared with normative expectations (16%), the group had a significantly greater frequency of at-risk scores (<1 SD) on measures of intelligence (28.7%), attention (35.2%), working memory (26.6%), processing speed (46.7%), and reading (25.8%). Including anesthesia exposure duration to linear regression models accounting for age at diagnosis, treatment intensity, and baseline IQ significantly increased the predicted variance for intelligence (r2 = 0.59), attention (r2 = 0.29), working memory (r2 = 0.31), processing speed (r2 = 0.44), and reading (r2 = 0.25; all P values <.001). CONCLUSIONS: In survivors of childhood medulloblastoma, a neurodevelopmentally vulnerable population, greater exposure to anesthesia significantly and independently predicts deficits in neurocognitive and academic functioning. When feasible, anesthesia exposure during treatment should be reduced.
Authors: Juraj Sprung; Randall P Flick; Slavica K Katusic; Robert C Colligan; William J Barbaresi; Katarina Bojanić; Tasha L Welch; Michael D Olson; Andrew C Hanson; Darrell R Schroeder; Robert T Wilder; David O Warner Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Marieke A de Ruiter; Rosa van Mourik; Antoinette Y N Schouten-van Meeteren; Martha A Grootenhuis; Jaap Oosterlaan Journal: Dev Med Child Neurol Date: 2012-11-15 Impact factor: 5.449
Authors: Tom G Hansen; Jacob K Pedersen; Steen W Henneberg; Dorthe A Pedersen; Jeffrey C Murray; Neil S Morton; Kaare Christensen Journal: Anesthesiology Date: 2011-05 Impact factor: 7.892
Authors: Caleb Ing; Charles DiMaggio; Andrew Whitehouse; Mary K Hegarty; Joanne Brady; Britta S von Ungern-Sternberg; Andrew Davidson; Alastair J J Wood; Guohua Li; Lena S Sun Journal: Pediatrics Date: 2012-08-20 Impact factor: 7.124
Authors: Vesna Jevtovic-Todorovic; Richard E Hartman; Yukitoshi Izumi; Nicholas D Benshoff; Krikor Dikranian; Charles F Zorumski; John W Olney; David F Wozniak Journal: J Neurosci Date: 2003-02-01 Impact factor: 6.167
Authors: Jane E Schreiber; Shawna L Palmer; Heather M Conklin; Donald J Mabbott; Michelle A Swain; Melanie J Bonner; Mary L Chapieski; Lu Huang; Hui Zhang; Amar Gajjar Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: Charles Reighard; Shaqif Junaid; William M Jackson; Ayesha Arif; Hannah Waddington; Andrew J O Whitehouse; Caleb Ing Journal: JAMA Netw Open Date: 2022-06-01
Authors: Ade Oyefiade; Iris Paltin; Cinzia R De Luca; Kristina K Hardy; David R Grosshans; Murali Chintagumpala; Donald J Mabbott; Lisa S Kahalley Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717
Authors: Victoria W Willard; Ibrahim Qaddoumi; Haitao Pan; Chia-Wei Hsu; Rachel C Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Kristin Goode; Kendra Parris; Sean Phipps Journal: J Clin Oncol Date: 2021-04-23 Impact factor: 50.717
Authors: Jeremy M Schraw; J P Woodhouse; Melanie B Bernhardt; Olga A Taylor; Terzah M Horton; Michael E Scheurer; M Fatih Okcu; Karen R Rabin; Philip J Lupo; Austin L Brown Journal: Sci Rep Date: 2021-10-04 Impact factor: 4.379